21-43058215-G-T
Variant names:
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000071.3(CBS):c.1397C>A(p.Ser466*) variant causes a stop gained change. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. S466S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 0)
Consequence
CBS
NM_000071.3 stop_gained
NM_000071.3 stop_gained
Scores
3
3
Clinical Significance
Conservation
PhyloP100: 6.42
Publications
0 publications found
Genes affected
CBS (HGNC:1550): (cystathionine beta-synthase) The protein encoded by this gene acts as a homotetramer to catalyze the conversion of homocysteine to cystathionine, the first step in the transsulfuration pathway. The encoded protein is allosterically activated by adenosyl-methionine and uses pyridoxal phosphate as a cofactor. Defects in this gene can cause cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria. This gene is a major contributor to cellular hydrogen sulfide production. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2016]
CBS Gene-Disease associations (from GenCC):
- classic homocystinuriaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, Orphanet, Myriad Women’s Health, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Pathogenic. The variant received 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 21-43058215-G-T is Pathogenic according to our data. Variant chr21-43058215-G-T is described in ClinVar as Pathogenic. ClinVar VariationId is 1073191.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000071.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CBS | MANE Select | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 17 | NP_000062.1 | P35520-1 | ||
| CBS | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 17 | NP_001171479.1 | P35520-1 | |||
| CBS | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 18 | NP_001171480.1 | P35520-1 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CBS | TSL:1 MANE Select | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 17 | ENSP00000381231.4 | P35520-1 | ||
| CBS | TSL:1 | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 17 | ENSP00000344460.5 | P35520-1 | ||
| CBS | TSL:1 | c.1397C>A | p.Ser466* | stop_gained | Exon 15 of 18 | ENSP00000352643.3 | P35520-1 |
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD3 genomes
Cov.:
0
GnomAD4 exome Cov.: 0
GnomAD4 exome
Cov.:
0
GnomAD4 genome Cov.: 0
GnomAD4 genome
Cov.:
0
ClinVar
ClinVar submissions
View on ClinVar Significance:Pathogenic
Revision:criteria provided, multiple submitters, no conflicts
Pathogenic
VUS
Benign
Condition
2
-
-
Classic homocystinuria (2)
1
-
-
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED (1)
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
PhyloP100
Vest4
ClinPred
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.